<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053165_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134148</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHHO2011NO14507</safetyreportid>
		<primarysourcecountry>NO</primarysourcecountry>
		<occurcountry>NO</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121210</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20110825</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121206</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2011NO14507</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>PHHO2011NO05342</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Kirsten</reportergivename>
			<reportermiddlename>Sundby</reportermiddlename>
			<reporterfamilyname>Hall</reporterfamilyname>
			<reporterorganization>Radiumhospitalet</reporterorganization>
			<reporterdepartment>Division of Cancer</reporterdepartment>
			<reportercountry>NO</reportercountry>
			<qualification>1</qualification>
			<sponsorstudynumb>CAMN107G2301</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientinvestigationnumb>6</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19590326</patientbirthdate>
			<patientheight>180</patientheight>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Percutaneous coronary intervention</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tobacco user</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Myocardial infarction</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Cardiac infarction</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Myocardial infarction</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Myocardial infarction</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110824</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20110829</reactionenddate>
				<reactionduration>6</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>161</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Arteriogram coronary</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood test</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Catheterisation cardiac</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Electrocardiogram</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>AMN107</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>128800</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Gastrointestinal stromal tumour</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110317</drugstartdate>
				<drugstartperiod>161</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20110824</drugenddate>
				<drugtreatmentduration>161</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>GLIMEPIRIDE</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>2 mg, QD</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>GLIMEPIRIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>METFORMIN</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>1000</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>1000 mg, BID</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>METFORMIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>APROVEL</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>300 mg, QD</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>IRBESARTAN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>NEXIUM</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>40</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>40 mg, QD</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ESOMEPRAZOLE MAGNESIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>OXIS</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FORMOTEROL FUMARATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>AEROBEC</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>BECLOMETASONE DIPROPIONATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>BRICANYL</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TERBUTALINE SULFATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ANTIHYPERTENSIVES</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NO INGREDIENTS/SUBSTANCES</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2011NO14507, is an initial report received on 25 Aug 2011, from clinical study CAMN107G2301.  This 52-year-old male subject (centre number 0461, subject number 6) was enrolled in a randomised, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult subjects with unresectable or metastatic gastrointestinal stromal tumors (GIST). The primary aim of the study is to compare progression free survival (PFS) of nilotinib and imatinib when used as initial therapy of unresectable and/or metastatic GIST in subjects either who have not received prior therapy with TKIs or who have recurrent GIST after stopping adjuvant treatment with imatinib.

The subject's medical history included diabetes, smoker, and hypertension. The subject had family history of myocardial infarction. Concomitant medications included glimepiride, metformin, Aprovel, Nexium, formoterol (oxis) inhalation, AeroBec inhalation, bricanyl inhalation, and antihypertensives. The subject was randomized to receive nilotinib in the core phase and received his first dose of study medication on 17 Mar 2011. On 24 Aug 2011, the subject experienced cardiac infarction, which resulted in hospitalisation on the same day. One day before hospitalisation, the subject experienced cardiac pain (tightness or squezzing in the chest) and dyspnea during sleep. On an unspecified date, ECG (electrocardiogram) ,coronaryangiography/cardiac catherization and blood test was done (results not available). The study medication was temporarily interrupted on 25 Aug 2011 due to the event. The subject underwent coronary angiography with PCI (percutaneous coronary intervention) and treated with clopidogrel hydrogen sulfate, enoxaparin, acetylsalicylic acid and metoprolol. The subject completely recovered from the event on 29 Aug 2011 and discharged on the same date. The event was considered serious (hospitalisation) by the investigator.  

The investigator did not suspect a relationship between the event and the study medication.

Follow up report received on 13 Sep 2011: Symptoms of the event, hospitalisation details, action taken with the study medication, concomitant medication details, treatment details and outcome of the event updated.

Follow up report received on 23 Sep 2011: Causality of the event was updated.

Follow up DR received on 03 Nov 2011: Event causality was updated.

Follow up ischemic heart disease was received on 06 Dec 2012: Updated medical history, family history, concomitant medications, and clinical course of the event including laboratory data.</narrativeincludeclinical>
				<sendercomment>Medical review and assessment complete. Novartis concurs with the investigator's assessment.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
